Near-fatal asthma in South Australia: Descriptive features and medication use

D. A. Campbell, C. G. Luke, G. McLennan, J. R. Coates, P. A. Frith, P. A. Gluyas, K. M. Latimer, A. J. Martin, R. E. Ruffin, P. M. Yellowlees, D. M. Roder

    Research output: Contribution to journalArticle

    22 Citations (Scopus)

    Abstract

    Background: Self-reported prior morbidity levels and medication use among survivors of a near-fatal asthma attack (NFA) were studied. Aims: To identify deficiencies in asthma management and opportunities for intervention. Methods: A hundred and twenty-seven consecutive patients aged 15 years or more presenting with a NFA to accident and emergency departments of teaching hospitals were interviewed. Results: High levels of morbidity due to asthma were reported. Most cases (79%) reported symptoms occurring at least weekly in the three months before their NFA. A mean of 20.8 days was reportedly lost from work, school or other usual daily activity in the 12 months before these events. Regular use of beta agonist as nebuliser solution was reported by 27% of cases, increasing to 34.5% in response to increased symptoms, while 41% reported use of nebulised beta agonist in response to the NFA event. Less than half of all cases (46%) reported using an inhaled corticosteroid on a regular basis. Oral corticosteroids were used by 33% of cases at times of increased symptoms in the preceding 12 months. However, only 7% of cases reported initiating or increasing oral corticosteroids at the time of the NFA. Conclusions: Despite high levels of prior asthma morbidity, regular preventive inhaled corticosteroid use was not widespread in this series of NFA asthmatics. By comparison, over-reliance on regular beta agonist medication was common. Oral corticosteroids were rarely commenced in response to the NFA.

    LanguageEnglish
    Pages356-362
    Number of pages7
    JournalAustralian and New Zealand journal of medicine
    Volume26
    Issue number3
    DOIs
    Publication statusPublished - 1 Jan 1996

    Keywords

    • Asthma
    • medications
    • morbidity
    • mortality
    • near-fatal

    ASJC Scopus subject areas

    • Internal Medicine

    Cite this

    Campbell, D. A. ; Luke, C. G. ; McLennan, G. ; Coates, J. R. ; Frith, P. A. ; Gluyas, P. A. ; Latimer, K. M. ; Martin, A. J. ; Ruffin, R. E. ; Yellowlees, P. M. ; Roder, D. M. / Near-fatal asthma in South Australia : Descriptive features and medication use. In: Australian and New Zealand journal of medicine. 1996 ; Vol. 26, No. 3. pp. 356-362.
    @article{928634aac56b4c2e8676e2cd5f9f61f0,
    title = "Near-fatal asthma in South Australia: Descriptive features and medication use",
    abstract = "Background: Self-reported prior morbidity levels and medication use among survivors of a near-fatal asthma attack (NFA) were studied. Aims: To identify deficiencies in asthma management and opportunities for intervention. Methods: A hundred and twenty-seven consecutive patients aged 15 years or more presenting with a NFA to accident and emergency departments of teaching hospitals were interviewed. Results: High levels of morbidity due to asthma were reported. Most cases (79{\%}) reported symptoms occurring at least weekly in the three months before their NFA. A mean of 20.8 days was reportedly lost from work, school or other usual daily activity in the 12 months before these events. Regular use of beta agonist as nebuliser solution was reported by 27{\%} of cases, increasing to 34.5{\%} in response to increased symptoms, while 41{\%} reported use of nebulised beta agonist in response to the NFA event. Less than half of all cases (46{\%}) reported using an inhaled corticosteroid on a regular basis. Oral corticosteroids were used by 33{\%} of cases at times of increased symptoms in the preceding 12 months. However, only 7{\%} of cases reported initiating or increasing oral corticosteroids at the time of the NFA. Conclusions: Despite high levels of prior asthma morbidity, regular preventive inhaled corticosteroid use was not widespread in this series of NFA asthmatics. By comparison, over-reliance on regular beta agonist medication was common. Oral corticosteroids were rarely commenced in response to the NFA.",
    keywords = "Asthma, medications, morbidity, mortality, near-fatal",
    author = "Campbell, {D. A.} and Luke, {C. G.} and G. McLennan and Coates, {J. R.} and Frith, {P. A.} and Gluyas, {P. A.} and Latimer, {K. M.} and Martin, {A. J.} and Ruffin, {R. E.} and Yellowlees, {P. M.} and Roder, {D. M.}",
    year = "1996",
    month = "1",
    day = "1",
    doi = "10.1111/j.1445-5994.1996.tb01922.x",
    language = "English",
    volume = "26",
    pages = "356--362",
    journal = "Australian and New Zealand Journal of Medicine",
    issn = "1444-0903",
    publisher = "Wiley-Blackwell",
    number = "3",

    }

    Campbell, DA, Luke, CG, McLennan, G, Coates, JR, Frith, PA, Gluyas, PA, Latimer, KM, Martin, AJ, Ruffin, RE, Yellowlees, PM & Roder, DM 1996, 'Near-fatal asthma in South Australia: Descriptive features and medication use', Australian and New Zealand journal of medicine, vol. 26, no. 3, pp. 356-362. https://doi.org/10.1111/j.1445-5994.1996.tb01922.x

    Near-fatal asthma in South Australia : Descriptive features and medication use. / Campbell, D. A.; Luke, C. G.; McLennan, G.; Coates, J. R.; Frith, P. A.; Gluyas, P. A.; Latimer, K. M.; Martin, A. J.; Ruffin, R. E.; Yellowlees, P. M.; Roder, D. M.

    In: Australian and New Zealand journal of medicine, Vol. 26, No. 3, 01.01.1996, p. 356-362.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Near-fatal asthma in South Australia

    T2 - Australian and New Zealand Journal of Medicine

    AU - Campbell, D. A.

    AU - Luke, C. G.

    AU - McLennan, G.

    AU - Coates, J. R.

    AU - Frith, P. A.

    AU - Gluyas, P. A.

    AU - Latimer, K. M.

    AU - Martin, A. J.

    AU - Ruffin, R. E.

    AU - Yellowlees, P. M.

    AU - Roder, D. M.

    PY - 1996/1/1

    Y1 - 1996/1/1

    N2 - Background: Self-reported prior morbidity levels and medication use among survivors of a near-fatal asthma attack (NFA) were studied. Aims: To identify deficiencies in asthma management and opportunities for intervention. Methods: A hundred and twenty-seven consecutive patients aged 15 years or more presenting with a NFA to accident and emergency departments of teaching hospitals were interviewed. Results: High levels of morbidity due to asthma were reported. Most cases (79%) reported symptoms occurring at least weekly in the three months before their NFA. A mean of 20.8 days was reportedly lost from work, school or other usual daily activity in the 12 months before these events. Regular use of beta agonist as nebuliser solution was reported by 27% of cases, increasing to 34.5% in response to increased symptoms, while 41% reported use of nebulised beta agonist in response to the NFA event. Less than half of all cases (46%) reported using an inhaled corticosteroid on a regular basis. Oral corticosteroids were used by 33% of cases at times of increased symptoms in the preceding 12 months. However, only 7% of cases reported initiating or increasing oral corticosteroids at the time of the NFA. Conclusions: Despite high levels of prior asthma morbidity, regular preventive inhaled corticosteroid use was not widespread in this series of NFA asthmatics. By comparison, over-reliance on regular beta agonist medication was common. Oral corticosteroids were rarely commenced in response to the NFA.

    AB - Background: Self-reported prior morbidity levels and medication use among survivors of a near-fatal asthma attack (NFA) were studied. Aims: To identify deficiencies in asthma management and opportunities for intervention. Methods: A hundred and twenty-seven consecutive patients aged 15 years or more presenting with a NFA to accident and emergency departments of teaching hospitals were interviewed. Results: High levels of morbidity due to asthma were reported. Most cases (79%) reported symptoms occurring at least weekly in the three months before their NFA. A mean of 20.8 days was reportedly lost from work, school or other usual daily activity in the 12 months before these events. Regular use of beta agonist as nebuliser solution was reported by 27% of cases, increasing to 34.5% in response to increased symptoms, while 41% reported use of nebulised beta agonist in response to the NFA event. Less than half of all cases (46%) reported using an inhaled corticosteroid on a regular basis. Oral corticosteroids were used by 33% of cases at times of increased symptoms in the preceding 12 months. However, only 7% of cases reported initiating or increasing oral corticosteroids at the time of the NFA. Conclusions: Despite high levels of prior asthma morbidity, regular preventive inhaled corticosteroid use was not widespread in this series of NFA asthmatics. By comparison, over-reliance on regular beta agonist medication was common. Oral corticosteroids were rarely commenced in response to the NFA.

    KW - Asthma

    KW - medications

    KW - morbidity

    KW - mortality

    KW - near-fatal

    UR - http://www.scopus.com/inward/record.url?scp=8944246798&partnerID=8YFLogxK

    U2 - 10.1111/j.1445-5994.1996.tb01922.x

    DO - 10.1111/j.1445-5994.1996.tb01922.x

    M3 - Article

    VL - 26

    SP - 356

    EP - 362

    JO - Australian and New Zealand Journal of Medicine

    JF - Australian and New Zealand Journal of Medicine

    SN - 1444-0903

    IS - 3

    ER -